Confirmed presentations (as of April 2015)

 

Animal models for assessing ALS therapy
Robert Brown, USA

The future of Neurotherapeutics: Stroke
Louis Caplan, USA

Informed consent in Alzheimer’s disease and other dementing conditions
Anjan Chatterjee, USA

Animal models for neurological diseases: Stroke
Michael Chopp, USA

The future of Neurotherapeutics: Infections
David Clifford, USA 

Autoimmune Diseases of the Synapse: Novel clinical paradigms, models of disease and therapeutic implications
Josep Dalmau, USA

When to use steroids therapy in the various VZV clinical presentations
Donald Gilden, USA

How to differentiate between organic and non-organic symptomatology of movement disorders
Mark Hallett, USA

Length of Multiple Sclerosis pivotal studies (panelist)
David Leppert, Switzerland

Round table discussion on orphan drugs
Paul Matthews, UK

Therapy of NeuroAIDS
Avi Nath, USA  

Therapy of Lyme disease and post Lyme Disease Syndrome
Andrew Pachner, USA 

Treatment of ataxia
Massimo Pandolfo, Belgium  

Viral and non viral vectors in gene therapy
Amos Panet, Israel 

Length of Multiple Sclerosis pivotal studies
Nancy Richert, USA 

Therapy of orphan neurological diseases (panelist)
John Richert, USA 

The perspectives of the new disease-modifying strategies in Alzheimer’s disease 
Elio Scarpini, Italy 

Animal models for neurological diseases: Multiple sclerosis
Subramaniam Sriram, USA  

Promise and obstacles of gene therapy in muscular dystrophies
Thomas Voit, USA 

Thymectomy in myasthenia
Gil Wolfe, USA